3,4'-bis-allyloxy-biphenyl | 131845-55-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4'-bis-allyloxy-biphenyl
• 英文别名: 1-prop-2-enoxy-3-(4-prop-2-enoxyphenyl)benzene
• CAS: 131845-55-1
• 化学式: C₁₈H₁₈O₂
• 分子量: 266.34
• InChiKey: NSQNHJJVZXXDJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,4'-bis-allyloxy-biphenyl 在 氯化二乙基铝 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 2,3'-diallyl-biphenyl-3,4'-diol 、 2,3'-diallyl-biphenyl-3,4'-diol
  参考文献：
  名称：

  METHOD OF PRODUCING BIPHENOLIC COMPOUND, NOVEL BIPHENYL COMPOUND AND SYNTHESIS METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE

  摘要：

  本发明公开了一种生产厚朴酚及其类似物的方法，以及由此制备的新颖中间体。还公开了一种用于治疗帕金森病的药物组合物，该组合物包含厚朴酚和/或其类似物。

  公开号：

  US20130303788A1
• 作为产物：
  描述：

  4-(3-甲氧基苯基)苯酚 在 三溴化硼 、 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 36.0h， 生成 3,4'-bis-allyloxy-biphenyl
  参考文献：
  名称：

  METHOD OF PRODUCING BIPHENOLIC COMPOUND, NOVEL BIPHENYL COMPOUND AND SYNTHESIS METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE

  摘要：

  本发明公开了一种生产厚朴酚及其类似物的方法，以及由此制备的新颖中间体。还公开了一种用于治疗帕金森病的药物组合物，该组合物包含厚朴酚和/或其类似物。

  公开号：

  US20130303788A1

文献信息

• Small Molecule NF-κB Inhibitors as Immune Potentiators for Enhancement of Vaccine Adjuvants
  作者：Brittany A. Moser、Yoseline Escalante-Buendia、Rachel C. Steinhardt、Matthew G. Rosenberger、Britteny J. Cassaidy、Nihesh Naorem、Alfred C. Chon、Minh H. Nguyen、Ngoctran T. Tran、Aaron P. Esser-Kahn

  DOI：10.3389/fimmu.2020.511513

  日期：——

  Adjuvants are added to vaccines to enhance the immune response and provide increased protection against disease. In the last decade, hundreds of synthetic immune adjuvants have been created, but many induce undesirable levels of proinflammatory cytokines including TNF-α and IL-6. Here we present small molecule NF-κB inhibitors that can be used in combination with an immune adjuvant to both decrease

  疫苗中添加佐剂可增强免疫反应并增强对疾病的保护。在过去的十年中，数百种合成免疫佐剂被创造出来，但许多都会诱导促炎细胞因子（包括 TNF-α 和 IL-6）达到不良水平。在这里，我们提出了小分子 NF-κB 抑制剂，可与免疫佐剂联合使用，以减少与耐受性差相关的标记物并改善疫苗接种的保护反应。此外，我们合成了和厚朴酚衍生物库，确定了几种有希望用于疫苗制剂的候选物。
• An expedient synthesis of honokiol and its analogues as potential neuropreventive agents
  作者：Subhankar Tripathi、Ming-Huan Chan、Chinpiao Chen

  DOI：10.1016/j.bmcl.2011.11.030

  日期：2012.1

  An efficient synthesis of honokiol with Suzuki-Miyaura cross coupling obtained an overall yield of 45%. The proposed approach successfully synthesized several structurally similar alkyl, alkenyl and alkynyl analogues, seven of which showed potential neuropreventive activity against MPP+-induced and CHP/TBHP oxidative stress induced neuroblastoma cell death. (C) 2011 Elsevier Ltd. All rights reserved.
• Synthesis of honokiol analogues and evaluation of their modulating action on VEGF protein secretion and telomerase-related gene expressions
  作者：María Sánchez-Peris、Juan Murga、Eva Falomir、Miguel Carda、Juan Alberto Marco

  DOI：10.1111/cbdd.12880

  日期：2017.4

  A group of 36 biphenyl derivatives structurally related to honokiol were synthesized by means of Suzuki coupling reactions. Their cytotoxicities were evaluated and compared to that of honokiol. Some of the compounds were then evaluated for their ability to downregulate the secretion of the VEGF protein and the expression of the VEGF, hTERT, and c‐Myc genes; the two latter involved in the activation of telomerase in tumoral cells. Some of the synthetized derivatives showed promising pharmacological features as they exhibited IC50 values in low micromolar range, good therapeutic margins, and a multiple mode of action on tumor cells based on the inhibition of VEGF and, at the same time, of the expression of genes related to the activation of telomerase.
• METHODS AND COMPOSITIONS COMPRISING AN NFKB INHIBITOR AND AN ADJUVANT
  申请人：THE UNIVERSITY OF CHICAGO

  公开号：US20210346495A1

  公开（公告）日：2021-11-11

  The current disclosure describes the use of NFkB inhibitors as immune potentiators in vaccine compositions comprising adjuvants. Accordingly, aspects of the disclosure relate to a method for vaccinating a subject comprising administering a NFkB inhibitor and an adjuvant (or a composition of the disclosure comprising NFkB and an adjuvant) to the subject. Further aspects relate to a method for inhibiting an inflammatory reaction associated with an adjuvant in a subject, the method comprising co-administering a NFkB inhibitor and an adjuvant (or a composition of the disclosure comprising NFkB and an adjuvant) to the subject. Yet further aspects relate to a pharmaceutical composition comprising a NFkB inhibitor and an adjuvant.
• [EN] METHODS AND COMPOSITIONS COMPRISING AN NFKB INHIBITOR AND AN ADJUVANT<br/>[FR] MÉTHODES ET COMPOSITIONS COMPORTANT UN INHIBITEUR DE NF-KB ET UN ADJUVANT
  申请人：UNIV CHICAGO

  公开号：WO2020118159A1

  公开（公告）日：2020-06-11

  The current disclosure describes the use of NFkB inhibitors as immune potentiators in vaccine compositions comprising adjuvants. Accordingly, aspects of the disclosure relate to a method for vaccinating a subject comprising administering a NFkB inhibitor and an adjuvant (or a composition of the disclosure comprising NFkB and an adjuvant) to the subject. Further aspects relate to a method for inhibiting an inflammatory reaction associated with an adjuvant in a subject, the method comprising co-administering a NFkB inhibitor and an adjuvant (or a composition of the disclosure comprising NFkB and an adjuvant) to the subject. Yet further aspects relate to a pharmaceutical composition comprising a NFkB inhibitor and an adjuvant.